Moving forward on quality of care: Role of decision modeling  by Neuhauser, Duncan & Napier, Kristine
48A JACC Vol. 14, No. 3 
September 1989:48A-50A 
Moving Forward on Quality of Care: Role of Decision Modeling 
DUNCAN NEUHAUSER, PHD, KRISTINE NAPIER, MPH 
Cleveland, Ohio 
Quality care reemerges as an issue amid the primary 
concern for cost. Primary problems revolve around 
whether treatments are efficacious and appropriate for the 
individual patient and whether the practice of medicine is 
Focusing on Quality Care 
Interest in medical care delivery topics and ideas waxes 
and wanes. With the recent growth of competition and the 
introduction of prospective payment, the talk was all of 
lower costs; that is to say, “cheap.” Now we have redis- 
covered quality of care. Quality is the fashionable subject. 
The Health Care Finance Administration is continuing to 
report adjusted hospital mortality data to the public. The 
Joint Commission of the Accreditation of Healthcare Orga- 
nizations is overhauling its approach to quality assessment. 
Many hospitals, health maintenance organizations and other 
groups are beginning to make major new investments in 
monitoring and documenting their quality of care. 
The problem of quality can be divided into three general 
areas: 
Are the treatments we provide efficacious? This is the 
realm of technology assessment and clinical trials. 
Do we provide the most appropriate treatment for each 
patient? This is the realm of decision analysis and 
decision modeling. 
Given efficacy and appropriateness, are we doing it right? 
This is the realm of skill, competence and accuracy. 
Data bases and tracking patient outcomes have rele- 
vance for this part of quality. 
Efficacy of treatment is not a new question. In fact, there 
are two controlled clinical trials in the Bible.* First Kings, 
*The reader should consult different translations of the Bible. The 
translators were not qualified biostatisticians and their translations differ in 
methodologically interesting ways, especially for Daniel. 
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being performed competently. A model is suggested for how 
these questions might be addressed. 
(J Am Coil Cardiol1989;14:48A-5OA) 
chapter 18, is a trial comparing the efficacy of sacrificing to 
one God or many. (Although the former was an explosive 
success, perhaps we would have a hard time replicating this 
trial today.) The second is a nutrition trial in the first chapter 
of Daniel, demonstrating the unhealthiness of impure food 
from King Nebuchadnezzar’s table. Both of these trials are 
worth studying from a methodologic point of view. 
Medical decision making goes back to 1690 and Sir 
William Petty. He performed a cost-benefit evaluation of 
moving people out of London during the plague (I 1. Concern 
for medical skill traces back to the code of Hammurabi (circa 
2000 B.C.). 
The New Environment 
Proving quality care. The burden of proof has changed 
when it comes to the quality of medical care. Although 
biostatisticians and epidemiologists do not talk about burden 
of proof, it is a central concern of lawyers. The burden of 
proof was once on regulators and planners to prove that a 
hospital was not perfect. Competition has shifted that bur- 
den to hospitals, health maintenance organizations and other 
care providers to prove their own quality of care. 
For many, the high (or low) watermark of the old burden 
of proof was in the mid-1970s when a community hospital in 
an eastern city suburb made headlines after it was discov- 
ered to have a 56% operative mortality rate for coronary 
artery bypass surgery. Hospital officials claimed that the 
high rate was a result of the fact that their patients were 
sicker than those treated elsewhere. This suburban hospital 
further claimed that nearby big city teaching hospitals ad- 
mitted only the “healthy” patients, and that their commu- 
nity hospital took the patients who were turned away. 
Hospitals and health maintenance organizations have 
been forced to utilize their own resources, tens of millions of 
dollars in some cases, to prove that their care is excellent. 
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These monies can support decision analysts and decision 
modelers. 
How the competitive environment is played out is seen in 
part by this simple referral model. 
Primary care --j Secondary care + Downstream providers 
(community (tertiary care. home 
hospitals) care, nursing homes, 
rehabilitation hospitals, etc.) 
Consider the following examples. The medical director of 
a primary care health center writes to six urology groups, 
asking about their routine costs and quality of care. Only the 
group with the most convincing answers will get approxi- 
mately 100 referrals a year. Here the burden of proof is 
clearly on the competing urologists. 
A university hospital wishing to develop a network of 
obstetric and gynecology groups wants to know how to 
choose the best group to work with and support. A health 
maintenance organization with 150,000 enrollees refers 4,000 
patient-days of care to downstream providers. The medical 
director guides those patients through contractual agree- 
ments. Another health maintenance organization has spent a 
lot of effort to develop computer-based reminders for its 
primary care physicians to remember routine tests and 
preventive measures as a way to ensure quality. 
Evaluating quality of referral care. There have been 
hospitals that rotationally (randomly?) assign patients to 
different home care agencies and that could use this proce- 
dure to evaluate the quality of home care. 
It would be rare to find a hospital with a systematic effort 
to challenge the nursing homes to which it refers to demon- 
strate the quality of their care. One of the most interesting 
ideas is a rehabilitation hospital that proposes the following 
to referring institutions: “We will take every other patient 
and you may refer the other patients to one of our compet- 
itors. We will measure the outcomes of interest to you if you 
get our competitor to do the same. There must be an 
independent outside auditor to ensure that the information 
collected is accurate. Compare our results with theirs, show 
us these results so we can learn and we will live by the 
resultant comparison.” 
This kind of upstream and downstream evaluation should 
be an obligation of all care providers. Those interested in 
promoting the use of decision models should develop them 
to meet the needs of provider organizations in this context, 
where the demonstration of good performance is essential 
for survival. 
The growth of multi-institution delivery systems, whether 
they be the Veterans Administration, the Armed Services, 
the Hospital Corporation of America, Sisters of Mercy or 
Kaiser Permanente, now face a “buyers’ market” for new 
physicians. These systems will soon have the power to 
define the kind of education they want their new physicians 
to have, and medical schools will be forced to respond to 
these desires. If these systems want physicians who use 
computers, are familiar with decision analysis and can 
evaluate clinical evidence of efficacy, medical school curric- 
ula and residency training programs will have to respond 
accordingly. 
Conversely, if all these systems just want nonquantitative 
ward “teddy bear-like” doctors, quantitative decision meth- 
ods may die a quiet, unnoticed death. In our opinion, it is 
only a matter of time before such delivery systems define the 
type of physician they wish to be known for and then make 
those wishes known to medical schools and the specialty 
boards (2). 
The question is not about clinical trials versus decision 
analysis versus large data bases versus skill assessment, but 
rather about how each of these can be combined in clinical 
settings. Here are some examples. 
Ongoing Patient Randomization 
For the last several years at Cleveland Metropolitan 
General Hospital, all new general internal medicine patients 
are randomly assigned to one of four (now three) teams of 
residents and attending physicians (firms). Physicians are 
randomly assigned to these firms. This arrangement has 
provided a vehicle for a series of clinical trials (3). This 
concept of ongoing randomization is also in place at Univer- 
sity Hospitals of Cleveland and Henry Ford Hospital, and is 
about to be started at Harborview Hospital in Seattle. When 
one combines such arrangements with the hospitals’ com- 
puterized management information systems capable of auto- 
matically aggregating study relevant data, the costs of clin- 
ical trials can be substantially reduced (4). 
Decision Analysis and Clinical Trials 
A previous decision analysis can be the basis for a clinical 
trial. The decision tree can define the relevant data points 
and probabilities. The tree can be used as the basis for the 
power analysis. The results of the clinical trial can be used to 
modify the tree, and a new trial can be started. Such an effort 
has been carried out at University Hospitals of Cleveland 
under the direction of Victoria Cargill, MD, who has used 
the ongoing randomization of patients. The decision tree and 
trial compared the use of residents and nurse practitioners in 
giving fecal occult blood tests. The pretrial probabilities 
derived from published reports have been corrected, and a 
new trial has been proposed. (There is a lot to recommend 
the joining of the decision modelers with internists respon- 
sible for ambulatory units and in-patient beds.) 
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Prospective Decision Models and Preferred 
Provider Organizations 
Developing computer-based decision rules with a physician 
override policy. A third party payer approached our Univer- 
sity Hospital’s Department of Obstetrics and Gynecology. If 
we could develop prospective decision rules for utilization 
review on >50% of all charges, the insurer would be willing 
to designate us as a preferred provider. By having the 
provider develop computer-based decision rules, the insurer 
would not have to pay for nurses to sit by telephones. 
granting or denying prior approval for admission. The in- 
surer does not want to be seen as “hassling” doctors. If the 
decision rules are computer-based, each patient decision 
leaves an “audit trail,” and follow-up information can build 
a data base that can be used to refine and update the decision 
models. The decision models needed to start this process 
have only to be better than those currently in use. This is no 
challenge as long as one is careful to allow the physicians to 
“override” the program. It is expected that these decision 
models will be constantly improved. Even so, there will 
always have to be an override policy. The physician can 
override the decision model answer. but has to be prepared 
to fully explain the reason for doing so. The degree of 
“hassle” involved in an override can be minor or massive, 
thus varying the physician’s enthusiasm for doing so. 
The insurer would be able to audit the decisions. There is 
a menu of possible rewards the insurer can provide through 
the preferred provider arrangement, including marketing, 
instant fee transfer to the physician’s account. or higher 
reimbursement or assarance of no retrospective denials. 
Evaluating a data base in obstetrics and gynecology. The 
eventual goal of our project is to develop decision rules for 
discharge diagnoses constituting at least 50% of the charges 
in obstetrics and gynecology. Patient population statistics 
and charges from Univercity Hospitals for January through 
March 1987 were used in our initial evaluation. This data 
base will be updated and expanded as further statistics 
become available. 
Available statistics indicate that 31% of the charges made 
in obstetrics and gynecology were for vaginal delivery 
(complicated and uncomplicated). Twenty-three percent of 
the charges were for cesarean section and 10% for hyster- 
ectomy. Including all deliveries and hysterectomies, we 
have succeeded in addressing 64% of all charges in obstetrics 
and gynecology. 
For all deliveries, the basic research question we will be 
asking is: Why do expected vaginal deliveries become ce- 
sarean section deliveries? Financially, this is of paramount 
significance. Our information indicates that, on the average, 
the charge of an uncomplicated vaginal delivery is $3,287. 
whereas that of an uncomplicated cesarean section delivery 
is $6,516. With complications, these charges increase to 
$4, I75 and $8,312 for vagina1 and cesarean section, respec- 
tively. 
Within our basic question, we will want to know what 
characterizes these patients who were not expected to need 
a cesarean section, which is the same as asking what are the 
risk factors for cesarean sections? The ultimate goal is to ask 
how we can modify these risk factors and possibly avoid 
cesarean section, or at least modify the risk factors leading 
to complicated cesarean section. 
For instance, we might be asking: How can we intervene 
with appropriate pharmacology? Should we intervene after a 
specified period of time has elapsed in one of the other stages 
of labor? Is there a patient characteristic that seems to 
predict with an exceptionally high degree of certainty that 
cesarean section will be necessary? In the latter case, 
perhaps an early cesarean section would avoid the costs 
produced by a lengthened stay on the labor and delivery 
ward or by complications produced by a prolonged course of 
labor or trial delivery. 
For the procedure of hysterectomy, we will differentiate 
the elective from the nonelective cases and then sort out the 
characteristics differentiating patients undergoing each pro- 
cedure. The ultimate question we are asking is: What influ- 
ences the cost per patient per day and per procedure, and 
how much of a change can we effect by modifying these risk 
factors? Much of the information we are utilizing is on-line 
with one of the computer-based support systems at Univer- 
sity Hospitals. Chart review will be necessary to complete 
the project. The reader must be warned that we may not be 
able to accomplish this. However, if we do not do so, it is 
only a matter of time before others will. 
Conclusions. Concern for quality is not a new problem. 
Quantitative decision models can be combined with clinical 
trials and data bases to have direct ongoing relevance for 
clinical care. However, trying to answer real problems 
means starting with the problem and finding the appropriate 
technique. rather than having a technique and searching for 
a use for it. 
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